IRINOTECAN 40MG/2ML INJECTION

Irinotecan 40mg/2ml Injection is a prescription anticancer medication classified as a topoisomerase I inhibitor. It is primarily used in the treatment of colorectal cancer and is also effective against various other solid tumors. This injectable formulation is commonly included in combination chemotherapy regimens to improve therapeutic outcomes in patients with advanced or metastatic cancers.

The active ingredient, irinotecan, works by interfering with the enzyme topoisomerase I, which is essential for DNA replication in rapidly dividing cancer cells. By inhibiting this enzyme, irinotecan causes DNA damage, leading to cancer cell death and slowing tumor progression. Due to its potent cytotoxic effects, irinotecan injection is administered intravenously by trained healthcare professionals in controlled oncology settings to ensure patient safety and optimal dosing.

Irinotecan Injection 40 mg/2 ml plays a vital role in modern cancer therapy protocols. This chemotherapy product is widely used in hospital oncology departments and cancer treatment centers as part of evidence-based treatment plans. Its proven efficacy in oncology care, combined with precise intravenous administration, makes Irinotecan Injection a critical product in the management of colorectal and solid tumor cancers.

Product Features

• Topoisomerase I inhibitor chemotherapy
• Used in colorectal and other solid tumors
• Interferes with cancer cell DNA replication
• Intravenous injectable formulation
• Used in combination with chemotherapy regimens
• Prescription-only oncology medication

How It Helps

• Inhibits topoisomerase I enzyme to prevent cancer cell DNA replication
• Promotes cancer cell death, helping slow tumor growth
• Enhances treatment effectiveness when used in combination with chemotherapy
• Plays a key role in the management of colorectal and other solid tumors